Merus N.V. (MRUS)

Market Cap	2.94B
Revenue (ttm)	35.93M
Net Income (ttm)	-244.56M
Shares Out	68.46M
EPS (ttm)	-3.98
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	605,265
Open	43.30
Previous Close	43.49
Day's Range	42.30 - 43.52
52-Week Range	22.26 - 61.61
Beta	1.12
Analysts	Strong Buy
Price Target	86.70 (+101.96%)
Earnings Date	Oct 31, 2024

About MRUS

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid t...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 19, 2016
• Employees: 229
• Stock Exchange: NASDAQ
• Ticker Symbol: MRUS
• Website: https://www.merus.nl

Financial Performance

In 2023, Merus's revenue was $43.95 million, an increase of 5.68% compared to the previous year's $41.59 million. Losses were -$154.94 million, 18.1% more than in 2022.

Analyst Forecast

According to 10 analysts, the average rating for MRUS stock is "Strong Buy." The 12-month stock price forecast is $86.7, which is an increase of 101.96% from the latest price.

Price Target

$86.7

(101.96% upside)

Analyst Consensus: Strong Buy